CAS No. : 106133-20-4

Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:I000310
Molecular Formula:C20H28N2O5S
Molecular Weight:408.51
Target:α1 receptor
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

Appearance:Solid powder
Purity: > 98%
Cat No:I000310
Cas No:106133-20-4

Tamsulosin is a selective α1 receptor antagonist.
Target: α1 receptor
Tamsulosin is a selective α1 receptor antagonist that has preferential selectivity for the α1A receptor in the prostate versus the α1B receptor in the blood vessels. Tamsulosin-treated patients had a 0.30-fold lower risk of developing acute urinary retention compared with control patients. None of the International Continence Society male questionnaire domain scores showed significant changes between the groups [1]. tamsulosin can be recommended for treating men after catheterization for AUR, and can reduce the likelihood of the need for re-catheterization [2].

1:Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (DIrecT Study). Yamanishi T, Asakura H, Seki N, Tokunaga S.Int J Urol. 2017 May 2. doi: 10.1111/iju.13359. [Epub ahead of print] PMID: 28466585
2:Unilateral choroidal detachment following the use of tamsulosin. Lubbers SM, Japing WJ.Can J Ophthalmol. 2017 Apr;52(2):e75-e77. doi: 10.1016/j.jcjo.2016.09.016. Epub 2017 Jan 13. No abstract available. PMID: 28457310
3:Tamsulosin for treatment of lower urinary tract symptoms in women: a systematic review and meta-analysis. Zhang HL, Huang ZG, Qiu Y, Cheng X, Zou XQ, Liu TT.Int J Impot Res. 2017 Apr 20. doi: 10.1038/ijir.2017.12. [Epub ahead of print] PMID: 28424499
4:Superparamagnetic graphene oxide-based dispersive-solid phase extraction for preconcentration and determination of tamsulosin hydrochloride in human plasma by high performance liquid chromatography-ultraviolet detection. Pashaei Y, Ghorbani-Bidkorbeh F, Shekarchi M.J Chromatogr A. 2017 May 26;1499:21-29. doi: 10.1016/j.chroma.2017.03.038. Epub 2017 Mar 19. PMID: 28410800
5:Clinical evaluation of tamsulosin in the relief of lower urinary tract symptoms in advanced prostate cancer patients. Zhang T, Wu H, Liu S, He W, Ding K.Int Urol Nephrol. 2017 Apr 13. doi: 10.1007/s11255-017-1591-1. [Epub ahead of print] PMID: 28409402
6:Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients. Kim SJ, Shin IS, Eun SJ, Whangbo TK, Kim JW, Cho YS, Kim JC.Int Neurourol J. 2017 Mar 24;21(1):29-37. doi: 10.5213/inj.1734826.413. PMID: 28361519 Free PMC Article
7:Effects of Tamsulosin and Tolterodine on double J stent-related symptoms: A double-blind, randomized, placebo-controlled trial. Moradi M, Abdi H, Ebrahimi S, Rezaee H, Kaseb K.SAGE Open Med. 2017 Feb 28;5:2050312117696436. doi: 10.1177/2050312117696436. eCollection 2017. PMID: 28344784 Free PMC Article
8:Should Kidney Stone Patients With Diagnosis by Ultrasonography Be Prescribed Tamsulosin? Hall MK, Sorenson M, Harper J.Ann Emerg Med. 2017 Apr;69(4):523-524. doi: 10.1016/j.annemergmed.2016.11.044. No abstract available. PMID: 28335927
9:Sildenafil citrate in combination with tamsulosin versus tamsulosin monotherapy for management of male lower urinary tract symptoms due to benign prostatic hyperplasia: A randomised, double-blind, placebo-controlled trial. Fawzi A, Kamel M, Salem E, Desoky E, Omran M, Elgalaly H, Sakr A, Maarouf A, Khalil S.Arab J Urol. 2016 Dec 29;15(1):53-59. doi: 10.1016/j.aju.2016.11.001. eCollection 2017 Mar. PMID: 28275519 Free PMC Article
10:[Management of ureteric colic with ketorolac and nifedipin vs. ketorolac and tamsulosin in the emergency room]. Montiel-Jarquín ÁJ, Rocha-Rocha VM, Solís-Mendoza HA, Romero-Figueroa MS, Etchegaray-Morales I, Alvarado-Ortega I.Rev Med Inst Mex Seguro Soc. 2017;55 Suppl 1:S20-S25. Spanish. PMID: 28212471
Recommended Products
  • CAS No. :130352-45-3
    Product Name:

    2-Cyclobuten-1-one, 4-ethynyl-4-hydroxy-2,3-dimethyl- (9CI)

    Cat No: M106806 View details
  • CAS No. :126748-58-1
    Product Name:


    Cat No: M106807 View details
  • CAS No. :130628-75-0
    Product Name:


    Cat No: M106808 View details
  • CAS No. :131803-37-7
    Product Name:


    Cat No: M106810 View details